Amylyx Pharmaceuticals, Inc.
NASDAQ: AMLX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joshua Cohen
- Employees
- 123
- Headquarters
- Cambridge, United States
- IPO year
- 2022
- Market cap
- $1.4B
- Website
- https://amylyx.com
Loading AMLX…
Loading profile data…Frequently asked questions about AMLX
What does Amylyx Pharmaceuticals, Inc. (AMLX) do?
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sod...
Where does AMLX trade?
Amylyx Pharmaceuticals, Inc. (AMLX) trades on the NASDAQ Global Select.
What sector is AMLX in?
Amylyx Pharmaceuticals, Inc. (AMLX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Amylyx Pharmaceuticals, Inc.?
Joshua Cohen is the chief executive officer of Amylyx Pharmaceuticals, Inc. (AMLX).
Where is Amylyx Pharmaceuticals, Inc. headquartered?
Amylyx Pharmaceuticals, Inc. is headquartered in United States.
Does AMLX pay a dividend?
Amylyx Pharmaceuticals, Inc. (AMLX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AMLX go public?
Amylyx Pharmaceuticals, Inc. (AMLX) completed its initial public offering in 2022.